CAPSTONE INVESTMENT ADVISORS, LLC
Position in DNLI — Denali Therapeutics Inc.
CIK 1426196
NEW YORK, NY
Position in DNLI
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$539,194
+$290,305 QoQ
Shares Held
20,964
+61.7% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#146
of 290 holders
Holding Since
Sep 2023
6 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CAPSTONE INVESTMENT ADVISORS, LLC holds $45,989,751 across 38 Biotechnology names. DNLI ranks #11 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
120,000 | $15,927,600 | |
| 2 | TECH |
BIO-TECHNE Corp
|
210,000 | $14,836,500 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
7,200 | $1,348,416 | |
| 4 | RXRX |
Recursion Pharmaceuticals, Inc.
|
222,378 | $816,127 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,240 | $773,189 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,448 | $719,265 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
12,611 | $692,848 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,899 | $571,655 |
All Filings in DNLI
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $539,194 | 20,964 | Shares | Defined | 2026-08-17 | |
| 2026-03-31 | $248,889 | 12,963 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $640,786 | 38,812 | Shares | Defined | 2026-02-17 | |
| 2024-03-31 | $405,085 | 19,741 | Shares | Sole | 2024-05-01 | |
| 2023-12-31 | $491,197 | 22,889 | Shares | Sole | 2024-02-12 | |
| 2023-09-30 | $775,007 | 37,567 | Shares | Sole | 2023-11-13 | |
| No filing history on record for this holder in this stock. | ||||||